WNT inhibitor IC-2 | 1402835-93-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: WNT inhibitor IC-2
• 英文别名: (6S,9aS)-N,6-dibenzyl-8-(naphthalen-1-ylmethyl)-4,7-dioxo-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide
• CAS: 1402835-93-1
• 化学式: C₃₃H₃₂N₄O₃
• 分子量: 532.642
• InChiKey: GGLYVDBOMUQXQM-XZWHSSHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  40
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  73
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES
  申请人：TERNANSKY Robert J.

  公开号：US20110105603A1

  公开（公告）日：2011-05-05

  In alternative embodiments the invention provides compositions and methods for ameliorating diseases and conditions having a beta-amyloid component, including Alzheimer's disease (AD), Vascular Dementia (VD), dementia, pre-dementia, Cognitive Dysfunction Syndrome (CDS) and loss of cognition in humans and in non-human animal. In alternative embodiment the invention provides analogs of AB-007 and its acid form E64c (loxistatin), their preparation, and pharmaceutical compositions thereof and methods of making and using same. In alternative embodiments compositions of the invention are deuterated analogs of AB-007 (or E64d) and E64c (or loxistatin). In alternative embodiments compositions of the invention are metabolically blocked forms as compared to AB-007 and loxistatin. In alternative embodiments compositions of the invention are used to ameliorate (including treat, slow, reverse or prevent) a disease or condition which can be ameliorated by partial or complete inhibition of a cysteine protease, e.g., AD, VD, CDS. The invention also provides alternative dosage forms and formulations for AB-007 and loxistatin, and for compounds of this invention, which can be used e.g., to treat AD, VD and CDS, in humans and in non-human animals.

  在另一种实施方案中，本发明提供了用于改善具有β-淀粉样成分的疾病和病况的组合物和方法，包括阿尔茨海默病（AD），血管性痴呆（VD），痴呆，前痴呆，认知功能障碍综合征（CDS）和人类和非人类动物的认知丧失。在另一种实施方案中，本发明提供了AB-007的类似物及其酸性形式E64c（loxistatin），它们的制备，以及其制备和使用的药物组合物和方法。在另一种实施方案中，本发明的组合物是AB-007（或E64d）和E64c（或loxistatin）的氘代类似物。在另一种实施方案中，本发明的组合物是与AB-007和loxistatin相比代谢阻滞的形式。在另一种实施方案中，本发明的组合物用于改善（包括治疗，减缓，逆转或预防）可以通过部分或完全抑制半胱氨酸蛋白酶（例如AD，VD，CDS）改善的疾病或病况。本发明还提供了AB-007和loxistatin的另一种剂型和配方，以及本发明化合物的剂型和配方，可用于治疗人类和非人类动物的AD，VD和CDS等疾病和病况。
• SYNTHESIS AND ANALYSIS OF NOVEL COMPOUND CAPABLE OF INDUCING DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELL INTO HEPATOCYTE
  申请人：Shiota Goshi

  公开号：US20140112892A1

  公开（公告）日：2014-04-24

  The purpose is to select low-molecular-weight compounds which are effective in inducing differentiation of mesenchymal stem cell into hepatocyte and to develop a safe differentiation-inducing method having excellent efficiency of differentiating mesenchymal stem cell into hepatocyte. Provided are at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; a differentiation inducer comprising at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; and a differentiation inducer comprising a compound represented by formula (8), a salt thereof, or a solvate of them.

  本发明旨在选择低分子量化合物，该化合物能有效地诱导间充质干细胞分化为肝细胞，并开发出一种安全的分化诱导方法，具有将间充质干细胞分化为肝细胞的卓越效率。提供了至少一种化合物，所述化合物选自由式（1）和（2）所表示的化合物组成的群体中的化合物，其盐或它们的溶剂化物；至少包括一种化合物的分化诱导剂，所述化合物选自由式（1）和（2）所表示的化合物组成的群体中的化合物，其盐或它们的溶剂化物；以及包括由式（8）所表示的化合物，其盐或它们的溶剂化物的分化诱导剂。
• Inhibitory effect of low molecular weight compound on cancer and fibrosis
  申请人：NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY

  公开号：US11213527B2

  公开（公告）日：2022-01-04

  A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof. Alternatively, a therapeutic drug for fibrosis can be used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof.

  获得了一种治疗恶性肿瘤、癌症干细胞或纤维化的新型治疗药物。用于恶性肿瘤或癌症干细胞的治疗药物包括至少一种选自由式（1）、（2）和（5）所代表的化合物、其盐或其溶液组成的组中的化合物。另外，还可以使用一种治疗纤维化的药物，其中包括至少一种选自由式（1）、（2）和（5）所代表的化合物、其盐或其溶液组成的组中的化合物。
• INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS
  申请人：NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY

  公开号：US20180028536A1

  公开（公告）日：2018-02-01

  A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof. Alternatively, a therapeutic drug for fibrosis can be used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof.
• US9555061B2
  申请人：——

  公开号：US9555061B2

  公开（公告）日：2017-01-31